Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Clinical Trial of IHL-675A to Assess Safety and Pharmacokinetics in Healthy Volunteers

Next Previous
Trial Profile

A Phase I Clinical Trial of IHL-675A to Assess Safety and Pharmacokinetics in Healthy Volunteers

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol/hydroxychloroquine (Primary) ; Cannabidiol; Hydroxychloroquine
  • Indications Adult respiratory distress syndrome
  • Focus Pharmacokinetics
  • Sponsors Incannex Healthcare

Most Recent Events

  • 21 Jul 2022 According to an Incannex Healthcare media release, this trial will be conducted at CMAX Clinical Research and managed by Avance Clinical.
  • 21 Jul 2022 According to an Incannex Healthcare media release, results from this trial will form part of three U.S. Food and Drug Administration ('FDA') investigational new drug ('IND') applications for each of the initial three indications the Company is pursuing for IHL-675A (rheumatoid arthritis, inflammatory bowel disease and lung inflammation).
  • 20 Jul 2022 According to an Incannex Healthcare media release, the company received approval from the Bellberry Human Research Ethics Committee ('HREC') to initiate this trial and patient recruitment is expected to start in August 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top